Adverts

Open Access Articles- Top Results for Pentostatin

Pentostatin

</th></tr></th></tr>
Pentostatin
200px
Systematic (IUPAC) name
(R)-3-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
Clinical data
Trade names Nipent
AHFS/Drugs.com monograph
MedlinePlus a692004
  • US: D (Evidence of risk)
Intravenous
Pharmacokinetic data
Bioavailability n/a
Protein binding 4%
Metabolism Hepatic, minor
Half-life 2.6 to 16 hours, mean 5.7 hours
Identifiers
53910-25-1 7pxY
L01XX08
PubChem CID 439693
DrugBank DB00552 7pxY
ChemSpider 388759 7pxY
UNII 395575MZO7 7pxY
KEGG D00155 7pxY
ChEMBL CHEMBL1580 7pxY
Chemical data
Formula C11H16N4O4
268.269 g/mol
 14pxY (what is this?)  (verify)

Pentostatin (or deoxycoformycin, trade name Nipent, manufactured by SuperGen) is an anticancer chemotherapeutic drug.[1]

Mechanism

It is classified as a purine analog, which is a type of antimetabolite.

It mimics the nucleoside adenosine and thus inhibits the enzyme adenosine deaminase, interfering with the cell's ability to process DNA.[2]

Cancer cells generally divide more often than healthy cells; DNA is highly involved in cell division (mitosis) and drugs which target DNA-related processes are therefore more toxic to cancer cells than healthy cells.

Uses

Pentostatin is used to treat hairy cell leukemia.[3] It is given by intravenous infusion once every two weeks for three to six months.

Additionally, pentostatin has been used to treat steroid-refractory acute and chronic graft-versus-host disease.[4]

Pentostatin is also used in chronic lymphocytic leukemia (CLL) patients who have relapsed.

References

  1. ^ Kay NE, Geyer SM, Call TG et al. (January 2007). "Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia". Blood 109 (2): 405–11. PMC 1785105. PMID 17008537. doi:10.1182/blood-2006-07-033274. 
  2. ^ Sauter C, Lamanna N, Weiss MA (September 2008). "Pentostatin in chronic lymphocytic leukemia". Expert Opin Drug Metab Toxicol 4 (9): 1217–22. PMID 18721115. doi:10.1517/17425255.4.9.1217. 
  3. ^ Cannon T, Mobarek D, Wegge J, Tabbara IA (October 2008). "Hairy cell leukemia: current concepts". Cancer Invest. 26 (8): 860–5. PMID 18798068. doi:10.1080/07357900801965034. 
  4. ^ Bolaños-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC, Lucas DM, Anders V, Phelps M, Grever MR, Vogelsang GB (April 2005). "Pentostatin in steroid-refractory acute graft-versus-host disease". J Clin Onc 23 (12): 2661–8. PMID 15837980. doi:10.1200/JCO.2005.06.130. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.